Florent Baudin1, Sebastien Gagnon2, Benjamin Crulli2, François Proulx2, Philippe Jouvet2, Guillaume Emeriaud3. 1. Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada. Pediatric Intensive Care Unit, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France. 2. Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada. 3. Department of Pediatrics, CHU Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada. guillaume.emeriaud@umontreal.ca.
Abstract
BACKGROUND: High-flow nasal cannula (HFNC) therapy is increasingly used in pediatric ICUs as an intermediate level of support between conventional oxygen delivery and noninvasive ventilation (NIV). The safety of HFNC has seldom been studied, and some cases of barotrauma have been reported. This retrospective study aims to describe HFNC use in a tertiary care pediatric ICU, with a focus on the complications associated with this therapy. METHODS: Between January 2013 and January 2014, all children <18 y old treated with HFNC in the pediatric ICU were included. Demographic data, HFNC settings, chest radiograph reports, and blood gas values were gathered from the electronic medical records. Episodes of pneumothorax, pneumomediastinum, and significant epistaxis were noted. Pneumothorax was distinguished from chest tube-related air leak (frequent after cardiac surgery), which was defined as a small pneumothorax with no clinical impact that resolved spontaneously after chest tube removal. RESULTS: During the 1-y study period, there were 177 HFNC episodes, involving 145 subjects with a median (interquartile range) age of 8 (2-28) months. HFNC was used as primary support in 31% of episodes, after extubation in 36% and after NIV in 18%. HFNC was administered exclusively for nitric oxide delivery in 16% of episodes. Two children (1%) developed new pneumothoraces that required chest tube insertion, whereas 5 (3%) chest tube-related air leaks were noted. One (0.6%) episode of significant epistaxis was noted. Among 6 preexisting pneumothoraces, none worsened under HFNC. Failure of HFNC occurred in 32 episodes, requiring transition to NIV in 28 cases and endotracheal intubation in 5 cases. CONCLUSIONS: Support with HFNC following a clinical protocol in pediatric ICUs was associated with a relatively low rate of complications. Since HFNC use is increasing, further evidence is needed to confirm its efficacy and safety.
BACKGROUND: High-flow nasal cannula (HFNC) therapy is increasingly used in pediatric ICUs as an intermediate level of support between conventional oxygen delivery and noninvasive ventilation (NIV). The safety of HFNC has seldom been studied, and some cases of barotrauma have been reported. This retrospective study aims to describe HFNC use in a tertiary care pediatric ICU, with a focus on the complications associated with this therapy. METHODS: Between January 2013 and January 2014, all children <18 y old treated with HFNC in the pediatric ICU were included. Demographic data, HFNC settings, chest radiograph reports, and blood gas values were gathered from the electronic medical records. Episodes of pneumothorax, pneumomediastinum, and significant epistaxis were noted. Pneumothorax was distinguished from chest tube-related air leak (frequent after cardiac surgery), which was defined as a small pneumothorax with no clinical impact that resolved spontaneously after chest tube removal. RESULTS: During the 1-y study period, there were 177 HFNC episodes, involving 145 subjects with a median (interquartile range) age of 8 (2-28) months. HFNC was used as primary support in 31% of episodes, after extubation in 36% and after NIV in 18%. HFNC was administered exclusively for nitric oxide delivery in 16% of episodes. Two children (1%) developed new pneumothoraces that required chest tube insertion, whereas 5 (3%) chest tube-related air leaks were noted. One (0.6%) episode of significant epistaxis was noted. Among 6 preexisting pneumothoraces, none worsened under HFNC. Failure of HFNC occurred in 32 episodes, requiring transition to NIV in 28 cases and endotracheal intubation in 5 cases. CONCLUSIONS: Support with HFNC following a clinical protocol in pediatric ICUs was associated with a relatively low rate of complications. Since HFNC use is increasing, further evidence is needed to confirm its efficacy and safety.
Authors: Colin M Rogerson; Aaron E Carroll; Wanzhu Tu; Tian He; Titus K Schleyer; Courtney M Rowan; Arthur H Owora; Eneida A Mendonca Journal: Respir Care Date: 2022-05-24 Impact factor: 2.339
Authors: Anna Cancelliere; Giada Procopio; Maria Mazzitelli; Elena Lio; Maria Petullà; Francesca Serapide; Maria Chiara Pelle; Chiara Davoli; Enrico Maria Trecarichi; Carlo Torti Journal: Clin Case Rep Date: 2021-04-09
Authors: Florent Baudin; Alexandra Buisson; Blandine Vanel; Bruno Massenavette; Robin Pouyau; Etienne Javouhey Journal: Ann Intensive Care Date: 2017-05-22 Impact factor: 6.925
Authors: Francesca Simioli; Anna Annunziata; Giorgio Emanuele Polistina; Antonietta Coppola; Valentina Di Spirito; Giuseppe Fiorentino Journal: Healthcare (Basel) Date: 2021-05-22
Authors: Bram Rochwerg; Sharon Einav; Dipayan Chaudhuri; Jordi Mancebo; Tommaso Mauri; Yigal Helviz; Ewan C Goligher; Samir Jaber; Jean-Damien Ricard; Nuttapol Rittayamai; Oriol Roca; Massimo Antonelli; Salvatore Maurizio Maggiore; Alexandre Demoule; Carol L Hodgson; Alain Mercat; M Elizabeth Wilcox; David Granton; Dominic Wang; Elie Azoulay; Lamia Ouanes-Besbes; Gilda Cinnella; Michela Rauseo; Carlos Carvalho; Armand Dessap-Mekontso; John Fraser; Jean-Pierre Frat; Charles Gomersall; Giacomo Grasselli; Gonzalo Hernandez; Sameer Jog; Antonio Pesenti; Elisabeth D Riviello; Arthur S Slutsky; Renee D Stapleton; Daniel Talmor; Arnaud W Thille; Laurent Brochard; Karen E A Burns Journal: Intensive Care Med Date: 2020-11-17 Impact factor: 17.440
Authors: Alvin Richards-Belle; Peter Davis; Laura Drikite; Richard Feltbower; Richard Grieve; David A Harrison; Julie Lester; Kevin P Morris; Paul R Mouncey; Mark J Peters; Kathryn M Rowan; Zia Sadique; Lyvonne N Tume; Padmanabhan Ramnarayan Journal: BMJ Open Date: 2020-08-04 Impact factor: 2.692